Engineered immune cells take aim at Hard-to-Treat lymphomas
NCT ID NCT02690545
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has come back or not responded to other therapies. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells carrying a protein called CD30. The goal is to find a safe dose and see if this therapy can keep the cancer from growing for at least two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.